Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sargramostim + naxitamab
- Development stage
- Unknown
- Lead developer
- Y-mAbs Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Sargramostim + naxitamab is a combination therapy used for the treatment of relapsed or refractory high-risk neuroblastoma in the bone or bone marrow in pediatric patients (1 year and older) and adults. Naxitamab is a humanized IgG1 monoclonal antibody that targets GD2, an oncofetal differentiation antigen highly expressed on neuroblastoma cells. Sargramostim (granulocyte-macrophage colony-stimulating factor, GM-CSF) is a cytokine that stimulates proliferation, differentiation, and functional activity of neutrophils, eosinophils, monocytes/macrophages. The combination enhances anti-tumor immune responses by both directly targeting tumor cells via antibody-dependent mechanisms (naxitamab) and stimulating myeloid cell activity (sargramostim). Naxitamab was developed at Memorial Sloan Kettering Cancer Center and is marketed as Danyelza by Y-mAbs Therapeutics[1][2][3][4][5][6][7][8].
- Brand names
- DANYELZALeukine
- Other names
- granulocyte-macrophage colony-stimulating factorGM-CSF
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)GD2
Beyond the preview
Go deeper on sargramostim + naxitamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sargramostim + naxitamab.